Transforming growth factor-beta-Smad signaling pathway (TGF-β-Smad pathway)

The Transforming growth factor-beta (TGF-β)-Smad signaling pathway is a fundamental intracellular cascade that regulates diverse biological processes, including cell proliferation, differentiation, apoptosis, and the epithelial-mesenchymal transition (EMT) (Massagué, 2012). The pathway is initiated when TGF-β ligands bind to a complex of transmembrane serine/threonine kinase receptors (Type I and Type II), leading to the phosphorylation of intracellular Smad proteins, specifically Smad2 and Smad3 (Derynck and Zhang, 2003). These phosphorylated receptor-activated Smads (R-Smads) then form a heteromeric complex with Smad4 and translocate into the nucleus to modulate the transcription of a vast array of target genes. In human disease, the TGF-β-Smad pathway plays a dual role in oncology, acting as a tumor suppressor in early stages while promoting metastasis and immune evasion in advanced cancers (Batlle and Massagué, 2019). Beyond cancer, its chronic activation is a primary driver of tissue fibrosis in the lungs, liver, and kidneys by stimulating the production of extracellular matrix proteins (Meng et al., 2016). Therapeutic strategies targeting this pathway include small molecule inhibitors of the TGF-β receptor I (ALK5) kinase, monoclonal antibodies that neutralize TGF-β ligands, and fusion proteins designed to trap circulating ligands (Teicher, 2021). However, systemic inhibition of this pleiotropic pathway carries notable risks, such as cardiotoxicity and the development of secondary skin tumors, which necessitates precise patient stratification and biomarker monitoring (Akhurst, 2017).

Other names

TGF-beta signaling pathwaySmad-dependent TGF-beta pathwayTGFB-SMAD signaling cascadeCanonical TGF-beta pathway

TGF-beta receptor type I kinase inhibition, TGF-beta ligand neutralization by monoclonal antibodies, TGF-beta ligand sequestration via decoy receptors (traps), Antisense oligonucleotide-mediated knockdown of TGF-beta expression